An FDA review related to the efficacy and safety of TCZ in rheumatoid arthritis, which included five randomized, double-blind, controlled trials (product registration studies), showed that approximately 50% of patients receiving TCZ present increases in ALT and AST of 1–3 times ULN. This evidence concerns the gene GPT and rheumatoid arthritis.